We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteomics Products May Reach $1.7 Billion by 2006

By Biotechdaily staff writers
Posted on 20 May 2002
By 2006, total revenues of proteomics-related products are forecast to approach US$1.7 billion, according to a new report from Business Communications Co. More...
(Proteomics: An Assessment of Technology and Commercial Potential, BCI, Inc., Norwalk, CT, USA). Since revenues for selected proteomics products totaled $720 million in 2001, the 2006 forecast would represent an average annual growth rate (AAGR) of just over 18%. This growth is largely due to a boom in scientific discoveries stemming from the human genome project and from advances in high-throughput technologies for protein studies. Other contributing factors are increases in funding for research and an increased interest in drug discovery from pharmaceutical and biotechnology companies.

Today, researchers can analyze protein expression in an entire cell rather than studying individual proteins, notes the report. Newer techniques allow scientists to isolate proteins and identify them more quickly. The development of new technologies for studying proteins has led to a rapid growth in industries supplying instruments and reagents for proteomics studies. In turn, this had made a variety of products easily available from companies eager to compete in the new market.

The market for mass spectroscopy for proteomics represents more than 40% of the total market and is forecast to double in five years, from $300 million in 2001 to $603 million by 2006. The nascent market for protein chips and bioinformatics is expected to rise from $114 million in 2001 to $275 million in 2006. Two-dimensional electrophoresis will see lower growth (11%), while capillary electrophoresis will rise at an AAGR of over 15% during the period.

Factors influencing the growth of the market for drug delivery instruments and services include the continuing investments of national governments into technology-based companies and technology-based not-for-profit research, the push by big pharmaceutical companies to fill their blockbuster pipelines, and efforts by small biotechnology companies to become bigger companies. As all of these groups continue their efforts, says BCC, they will in turn drive the development of new instruments and new technologies.





Related Links:
BCC

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.